Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	380610-27-5
M.W :	145.36 kD
SMILES Code :	NONE
Synonyms :	Pertuzumab(anti-HER2)
MDL No. :	N/A

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319
Precautionary Statements:	P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

ATI cells	1 μg/ml	1, 3 or 24 hours	Inhibition of ErbB2-ErbB3 dimerization, reduction in AKT and ERK1/2 phosphorylation	Cancer Res. 2015 Sep 1;75(17):3554-67
Bowes cells	1 μg/ml	1, 3 or 24 hours	Inhibition of ErbB2-ErbB3 dimerization, reduction in AKT and ERK1/2 phosphorylation	Cancer Res. 2015 Sep 1;75(17):3554-67
CHL-1 cells	1 μg/ml	1, 3 or 24 hours	Inhibition of ErbB2-ErbB3 dimerization, reduction in AKT and ERK1/2 phosphorylation	Cancer Res. 2015 Sep 1;75(17):3554-67
NCI-N87 gastric cancer cells	25 µM	1.5 hours	To investigate the effect of lovastatin pretreatment on the binding of Pertuzumab to NCI-N87 gastric cancer cell membranes. Results showed that lovastatin pretreatment significantly increased membrane-bound Pertuzumab and reduced internalized radioactivity.	J Nucl Med. 2019 Nov;60(11):1569-1578
MDA-MB-175	0.5 mg/mL	12 days	To evaluate the effect of CT-P6 and RTZ alone or in combination with pertuzumab on cell proliferation. Results showed that CT-P6 and RTZ had similar effects on proliferation inhibition, and synergistic effects when combined with pertuzumab.	Breast. 2022 Apr;62:1-9
LK2 cells	10 mg/mL	1-hour pretreatment	Reversed erdaﬁtinib resistance mediated by adipocyte precursor-conditioned medium (CM) via inhibiting HER3/HER2 dimerization.	Cancer Res. 2024 Mar 4;84(5):725-740
RT112 cells	10 mg/mL	1-hour pretreatment	Reversed erdaﬁtinib resistance mediated by adipocyte precursor-conditioned medium (CM) via inhibiting HER3/HER2 dimerization.	Cancer Res. 2024 Mar 4;84(5):725-740
RT4 cells	10 mg/mL	1-hour pretreatment	Reversed erdaﬁtinib resistance mediated by adipocyte precursor-conditioned medium (CM) via inhibiting HER3/HER2 dimerization.	Cancer Res. 2024 Mar 4;84(5):725-740
Caov3 cells	25 μg/mL	30 minutes	To evaluate the binding affinity of Pertuzumab to HER2, results showed Caov3 cells had lower HER2 expression and binding affinity	Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1296-1305
OVCAR3 cells	25 μg/mL	30 minutes	To evaluate the binding affinity of Pertuzumab to HER2, results showed OVCAR3 cells had lower HER2 expression and binding affinity	Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1296-1305
SKOV3 cells	25 μg/mL	30 minutes	To evaluate the binding affinity of Pertuzumab to HER2, results showed SKOV3 cells had the highest HER2 expression and binding affinity	Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1296-1305
USPC ARK-6	2.5 µg/ml	5 hours	Evaluate Pertuzumab-induced ADCC effect, results showed that in HER2/neu low-expressing USPC cells, Pertuzumab induced weaker ADCC effects, but the combination with Trastuzumab significantly enhanced ADCC effects.	Br J Cancer. 2010 Jan 5;102(1):134-43
USPC ARK-5	2.5 µg/ml	5 hours	Evaluate Pertuzumab-induced ADCC effect, results showed that in HER2/neu low-expressing USPC cells, Pertuzumab induced weaker ADCC effects, but the combination with Trastuzumab significantly enhanced ADCC effects.	Br J Cancer. 2010 Jan 5;102(1):134-43
USPC ARK-4	2.5 µg/ml	5 hours	Evaluate Pertuzumab-induced ADCC effect, results showed that in HER2/neu low-expressing USPC cells, Pertuzumab induced weaker ADCC effects, but the combination with Trastuzumab significantly enhanced ADCC effects.	Br J Cancer. 2010 Jan 5;102(1):134-43
USPC ARK-3	2.5 µg/ml	5 hours	Evaluate Pertuzumab-induced ADCC effect, results showed that in HER2/neu high-expressing USPC cells, Pertuzumab and Trastuzumab induced similar ADCC effects.	Br J Cancer. 2010 Jan 5;102(1):134-43
USPC ARK-2	2.5 µg/ml	5 hours	Evaluate Pertuzumab-induced ADCC effect, results showed that in HER2/neu high-expressing USPC cells, Pertuzumab and Trastuzumab induced similar ADCC effects.	Br J Cancer. 2010 Jan 5;102(1):134-43
USPC ARK-1	2.5 µg/ml	5 hours	Evaluate Pertuzumab-induced ADCC effect, results showed that in HER2/neu high-expressing USPC cells, Pertuzumab and Trastuzumab induced similar ADCC effects.	Br J Cancer. 2010 Jan 5;102(1):134-43
SKBR3	0.5 mg/mL	7 days	To evaluate the effect of CT-P6 and RTZ alone or in combination with pertuzumab on cell proliferation. Results showed that CT-P6 and RTZ had similar effects on proliferation inhibition, and synergistic effects when combined with pertuzumab.	Breast. 2022 Apr;62:1-9
BT-474	0.5 mg/mL	7 days	To evaluate the effect of CT-P6 and RTZ alone or in combination with pertuzumab on cell proliferation. Results showed that CT-P6 and RTZ had similar effects on proliferation inhibition, and synergistic effects when combined with pertuzumab.	Breast. 2022 Apr;62:1-9

Nude mice	BT474 human breast cancer xenograft model	Intraperitoneal injection	10 mg/kg	Once a week for 5 weeks	To evaluate the antitumor efficacy of scIgG-P and intact IgG-P in vivo, results showed that scIgG-P had significantly less tumor inhibition efficacy than intact IgG-P	Breast Cancer Res. 2018 Jun 1;20(1):43
Athymic mice	CHL-1 xenograft model	Intraperitoneal	200 μg/mouse	Every 3 days for 24 days	Inhibition of tumor growth, reduction in Ki67 and pS473 AKT expression	Cancer Res. 2015 Sep 1;75(17):3554-67
Mice	GXA 3054 PDX model	Intravenous	30 mg/kg	Twice weekly for five weeks	Evaluate the antitumor activity of Pertuzumab in HER2-high gastric cancer models	Nat Commun. 2023 Mar 13;14(1):1394
CB17-SCID mice	Bladder cancer xenograft model	Intravenous injection (three times a week)	5 mg/kg	Three times a week until the experimental endpoint (day 37)	Combination therapy of pertuzumab and erda?tinib significantly prolonged survival of RT4-NRG1 xenograft-bearing mice and reduced tumor Ki-67 expression.	Int J Cancer. 2014 Mar 15;134(6):1300-10
CB17-SCID mice	Bladder cancer xenograft model	Intravenous injection (three times a week)	5 mg/kg	Three times a week until the experimental endpoint (day 37)	Combination therapy of pertuzumab and erda?tinib significantly prolonged survival of RT4-NRG1 xenograft-bearing mice and reduced tumor Ki-67 expression.	Cancer Res. 2024 Mar 4;84(5):725-740
Nude mice	NCI-N87 gastric cancer xenograft model	Oral	8.3 mg/kg	12 hours before and at the same time as injection, lasting 48 hours	To evaluate the effect of lovastatin pretreatment on tumor uptake of Pertuzumab in NCI-N87 gastric cancer xenograft models. Results showed that lovastatin pretreatment significantly increased tumor uptake of Pertuzumab and achieved high-contrast images at 48 hours post-injection.	J Nucl Med. 2019 Nov;60(11):1569-1578

{[proInfo.proName]}

CAS No.: 380610-27-5

{[proInfo.proName]}

CAS No.: 380610-27-5

Alternative Products

Product Details of Pertuzumab

Safety of Pertuzumab

Related Pathways of Pertuzumab

Isoform Comparison

Biological Activity

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT00096941	Solid Cancers	PHASE2	COMPLETED	2025-10-07	-
NCT02411344	Endocrine Sensitive HER2+/HR+ ... More >>Breast Cancer Less <<	PHASE2	COMPLETED	2018-01-12	Policlinico Vittorio Emanuele,... More >> Catania, CT, Italy\|Arcispedale S. Anna, Cona, FE, Italy\|Istituto Europeo di Oncologia, Milano, MI, Italy\|Istituto Nazionale Tumori, Milano, MI, Italy\|Ospedale "Guglielmo da Saliceto", Piacenza, PC, Italy\|Istituto Oncologico Veneto, Oncologia Medica 2, Padova, PD, 35128, Italy\|Arcispedale S. Maria Nuova, Reggio Emilia, RE, Italy\|A. O. U. Santa Maria della Misericordia, Udine, UD, Italy Less <<
NCT00063154	Non-small Cell Lung Cancer	PHASE2	COMPLETED	2025-04-05	Arizona Cancer Center, Scottsd... More >>ale, Arizona, 85258, United States\|Arizona Cancer Center, Tucson, Arizona, 85724-5024, United States\|Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California, 90048, United States\|University of California Davis Cancer Center, Sacramento, California, 95817, United States\|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States\|Memorial-Sloan Kettering Cancer Center, New York, New York, 10021-6007, United States\|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, 37232-5536, United States\|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States Less <<
NCT02480010	Prostate Cancer	PHASE2	TERMINATED	2025-09-05	Lyon, 69008, France\|Montpellie... More >>r, 34298, France\|Berlin, 12203, Germany\|Parma, 43100, Italy\|Roma, 00152, Italy\|Rotterdam, 3075 EA, Netherlands\|Barcelona, 08035, Spain\|Valencia, 46009, Spain\|Cardiff, CF14 2TL, United Kingdom\|Sutton, SM2 5PT, United Kingdom\|Weston Super Mare, BS23 4TQ, United Kingdom Less <<
NCT02491892	Breast Cancer	PHASE2	COMPLETED	2025-04-05	Camperdown, 2050, Australia\|Fi... More >>tzroy, 3065, Australia\|Geelong, 3220, Australia\|Namur, 5000, Belgium\|Helsinki, 00029, Finland\|Tampere, 33520, Finland\|Hamburg, 20246, Germany\|Herne, 44625, Germany\|München, 81675, Germany\|Milano, 20133, Italy\|Parma, 43100, Italy\|Amsterdam, 1081 HV, Netherlands\|Barcelona, 08035, Spain\|Barcelona, 08907, Spain\|Valencia, 46009, Spain\|Edinburgh, EH4 2XU, United Kingdom\|London, SE1 9RT, United Kingdom\|Manchester, M20 4BX, United Kingdom Less <<
NCT02266173	Breast Cancer		COMPLETED	2021-03-08	Inje university Haeundae Paik ... More >>Hospital, Busan, 48108, Korea, Republic of\|Pusan National University Hospital, Busan, 49241, Korea, Republic of\|Kosin University Gospel Hospital, Busan, 49267, Korea, Republic of\|Kyungpook National University Chilgok Hospital, Daegu, 41404, Korea, Republic of\|Keimyung University Dongsan Medical Center, Daegu, 41931, Korea, Republic of\|Chungnam National University Hospital, Daejeon, 35015, Korea, Republic of\|National Health Insurance Service Ilsan Hospital, Gyeonggi-do, 10408, Korea, Republic of\|Hallym University Sacred Heart Hospital, Gyeonggi-do, 14068, Korea, Republic of\|Soonchunhyang University Bucheon Hospital, Gyeonggi-do, 14584, Korea, Republic of\|St. Vincent's Hospital, Gyeonggi-do, 16247, Korea, Republic of\|Ajou University Medical Center, Gyeonggi-do, 16499, Korea, Republic of\|The Catholic University of Korea Bucheon St. Mary's Hospital, Gyeonggi-do, Korea, Republic of\|Pusan National University Yangsan Hospital, Gyeongsangnam-do, 50612, Korea, Republic of\|Catholic Univ. of Incheon St.Mary's Hospital, Incheon, 21431, Korea, Republic of\|Inha University Hospital, Incheon, 22332, Korea, Republic of\|Gil Hospital. Gachon University, Incheon, 405-760, Korea, Republic of\|Catholic Kwandong University International St. Mary'S Hospital., Incheon, Korea, Republic of\|Chonnam National University Hwasun Hospital, Jeollanam-do, 58128, Korea, Republic of\|Wonkwang University School of Medicine & Hospital, Jeonlabuk-do, 54538, Korea, Republic of\|Seoul National University Bundang Hospital, Seongnam-si, 13605, Korea, Republic of\|Samsung Medical Center, Seoul, (0)6351, Korea, Republic of\|Inje University, Sanggye-Paik Hospital, Seoul, 01757, Korea, Republic of\|Korea Cancer Center Hospital of Korea Institute of Radiological and Medical Sciences, Seoul, 01812, Korea, Republic of\|Korea University Anam Hospital, Seoul, 02841, Korea, Republic of\|Seoul National University Hospital, Seoul, 03080, Korea, Republic of\|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of\|Konkuk University Medical Center, Seoul, 05030, Korea, Republic of\|Gangdong Kyung Hee University Hospital, Seoul, 05278, Korea, Republic of\|Asan Medical Center, Seoul, 05505, Korea, Republic of\|Gangnam Severance Hospital, Seoul, 06273, Korea, Republic of\|Seoul St Mary's Hospital, Seoul, 06591, Korea, Republic of\|ChungAng University Hospital, Seoul, 06973, Korea, Republic of\|Yeouido St. Mary's Hospital, Seoul, 07345, Korea, Republic of\|Ewha Womans University Mokdong Hospital, Seoul, 07985, Korea, Republic of\|Korea University Guro Hospital, Seoul, 08308, Korea, Republic of\|SMG-SNU Boramae Medical Center, Seoul, 156-707, Korea, Republic of\|Ulsan University Hosiptal, Ulsan, 44033, Korea, Republic of Less <<
NCT05891561	Breast Cancer	PHASE2	RECRUITING	2025-12-26	Shanghai Jiaotong University S... More >>chool of Medicine affiliated Ruijin Hospital, Shanghai, Shanghai, 200025, China Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed